314 related articles for article (PubMed ID: 27566443)
1. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.
Ho AL; Dunn L; Sherman EJ; Fury MG; Baxi SS; Chandramohan R; Dogan S; Morris LG; Cullen GD; Haque S; Sima CS; Ni A; Antonescu CR; Katabi N; Pfister DG
Ann Oncol; 2016 Oct; 27(10):1902-8. PubMed ID: 27566443
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance.
Mitani Y; Li J; Rao PH; Zhao YJ; Bell D; Lippman SM; Weber RS; Caulin C; El-Naggar AK
Clin Cancer Res; 2010 Oct; 16(19):4722-31. PubMed ID: 20702610
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
Ho AL; Foster NR; Deraje Vasudeva S; Katabi N; Antonescu CR; Frenette GP; Pfister DG; Erlichman C; Schwartz GK
Cancer; 2024 Mar; 130(5):702-712. PubMed ID: 37947157
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
6. MYB-NFIB gene fusions identified in archival adenoid cystic carcinoma tissue employing NanoString analysis: an exploratory study.
McIntyre JB; Ko JJ; Siever J; Chan AMY; Simpson RHW; Hao D; Lau HY
Diagn Pathol; 2019 Jul; 14(1):78. PubMed ID: 31301736
[TBL] [Abstract][Full Text] [Related]
7. MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features.
D'Alfonso TM; Mosquera JM; MacDonald TY; Padilla J; Liu YF; Rubin MA; Shin SJ
Hum Pathol; 2014 Nov; 45(11):2270-80. PubMed ID: 25217885
[TBL] [Abstract][Full Text] [Related]
8. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
Mitani Y; Liu B; Rao PH; Borra VJ; Zafereo M; Weber RS; Kies M; Lozano G; Futreal PA; Caulin C; El-Naggar AK
Clin Cancer Res; 2016 Feb; 22(3):725-33. PubMed ID: 26631609
[TBL] [Abstract][Full Text] [Related]
9. Study of MYB-NFIB chimeric gene expression, tumor angiogenesis, and proliferation in adenoid cystic carcinoma of salivary gland.
Ono J; Okada Y
Odontology; 2018 Jul; 106(3):238-244. PubMed ID: 29243184
[TBL] [Abstract][Full Text] [Related]
10. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma.
Persson M; Andrén Y; Moskaluk CA; Frierson HF; Cooke SL; Futreal PA; Kling T; Nelander S; Nordkvist A; Persson F; Stenman G
Genes Chromosomes Cancer; 2012 Aug; 51(8):805-17. PubMed ID: 22505352
[TBL] [Abstract][Full Text] [Related]
11. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma.
Rettig EM; Tan M; Ling S; Yonescu R; Bishop JA; Fakhry C; Ha PK
Laryngoscope; 2015 Sep; 125(9):E292-9. PubMed ID: 25963073
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
13. New developments in the molecular pathogenesis of head and neck tumors: a review of tumor-specific fusion oncogenes in mucoepidermoid carcinoma, adenoid cystic carcinoma, and NUT midline carcinoma.
Bhaijee F; Pepper DJ; Pitman KT; Bell D
Ann Diagn Pathol; 2011 Feb; 15(1):69-77. PubMed ID: 21238915
[TBL] [Abstract][Full Text] [Related]
14. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.
Tchekmedyian V; Sherman EJ; Dunn L; Tran C; Baxi S; Katabi N; Antonescu CR; Ostrovnaya I; Haque SS; Pfister DG; Ho AL
J Clin Oncol; 2019 Jun; 37(18):1529-1537. PubMed ID: 30939095
[TBL] [Abstract][Full Text] [Related]
16. The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Voss MH; Bhatt RS; Plimack ER; Rini BI; Alter RS; Beck JT; Wilson D; Zhang X; Mutyaba M; Glasser C; Attie KM; Sherman ML; Pandya SS; Atkins MB
Clin Cancer Res; 2017 Jul; 23(14):3557-3565. PubMed ID: 28031424
[No Abstract] [Full Text] [Related]
17. Small Subset of Adenoid Cystic Carcinoma of the Skin Is Associated With Alterations of the MYBL1 Gene Similar to Their Extracutaneous Counterparts.
Kyrpychova L; Vanecek T; Grossmann P; Martinek P; Steiner P; Hadravsky L; Belousova IE; Shelekhova KV; Svajdler M; Dubinsky P; Michal M; Kazakov DV
Am J Dermatopathol; 2018 Oct; 40(10):721-726. PubMed ID: 29570128
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.
Locati LD; Cavalieri S; Bergamini C; Resteghini C; Alfieri S; Calareso G; Bossi P; Perrone F; Tamborini E; Quattrone P; Granata R; Galbiati D; Platini F; Orlandi E; Mariani L; Licitra L
Head Neck; 2019 Oct; 41(10):3670-3676. PubMed ID: 31355973
[TBL] [Abstract][Full Text] [Related]
19. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics.
von Holstein SL; Fehr A; Persson M; Therkildsen MH; Prause JU; Heegaard S; Stenman G
Ophthalmology; 2013 Oct; 120(10):2130-8. PubMed ID: 23725736
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
